Table 1. Sociodemographic and clinical characteristics of PsA patients treated with anti-TNF drugs at Belo Horizonte Specialty Pharmacy.
| Variables | Total (197) |
|---|---|
| Sex - n (%) | |
| Female | 113 (57.4) |
| Male | 84 (42.6) |
| Age in years - mean (SD) | 50.83 (SD=11.27) |
| Disease time - mean (SD) | 5.96 (SD=7.51) |
| Ethnicity n (%) | |
| White | 103 (52.3) |
| Brown | 66 (33.5) |
| Others | 28 (14.2) |
| Marital Status n (%) | |
| Single | 49 (25.1) |
| Married | 114 (58.5) |
| Others | 31 (16.4) |
| Schooling n (%) | |
| Illiterate until complete elementary school | 55 (28.2) |
| High school | 78 (40.0) |
| Higher education | 62 (31.8) |
| Anti-TNF n (%) | |
| Adalimumab | 112 (56.8) |
| Etanercept | 64 (32.5) |
| Infliximab | 21 (10.7) |
| Current drugs n (%) | |
| csDMARDs | 86 (43.6) |
| NSAIDs | 48 (24.4) |
| Corticosteroids | 53 (26.9) |
| Previous drugs n (%) | |
| csDMARDs | 152 (78.4) |
| bDMARDs | 40 (20.5) |
| CDAI - mean (SD) | 22.58 (SD=16.79) |
| BASDAI - mean (SD) | 5.28 (SD=2.53) |
| HAQ-DI - mean (SD) | 1.21 (SD=0.71) |
| EQ-5D - mean (SD) | 0.65 (SD=0.18) |
| EQ-5D VAS - mean (SD) | 62.92 (SD=20.30) |
| Comorbidities n (%) | |
| 0 | 51 (25.9) |
| 1 | 55 (27.9) |
| > 1 | 91 (46.2) |
VAS: Visual Analogic Scale; BASDAI: Bath Ankylosing Spondylitis Activity Index; bDMARD: Biological disease-modifying antirheumatic drug; CDAI: Clinical Disease Activity Index; EQ-5D: EuroQol-5 dimensions; HAQ: Health assessment questionnaire; n: Number of patients; NSAIDs: Nonsteroidal anti-inflammatory drugs; SD: Standard deviation; csDMARD: Conventional synthetic disease-modifying antirheumatic drug.